Literature DB >> 12391215

Defective T cell priming associated with aging can be rescued by signaling through 4-1BB (CD137).

Pratima Bansal-Pakala1, Michael Croft.   

Abstract

Aging is associated with an increased susceptibility to infectious agents and correlates with a decreased ability to mount an immune response. It has been postulated that the major defect is related to a reduced capacity of an aged T cell to proliferate and to survive after encounter with Ag. This is similar to the phenotype associated with T cell tolerance in young adults. In this study, we determined whether targeting 4-1BB (CD137), a member of the TNFR family implicated in providing expansion and survival signals to T cells, can rescue defective priming in aged and tolerized animals. Agonist Abs to 4-1BB injected in vivo were capable of preventing CD4 T cell tolerance to soluble peptide in young mice. Moreover, anti-4-1BB rescued defective priming of aged TCR transgenic CD4 T cells responding to peptide Ag in a young host, and as importantly, anti-4-1BB completely restored T cell priming to protein Ag in nontransgenic aged mice. These studies demonstrate that 4-1BB, and potentially other costimulatory members of the TNFR family, are targets for therapies aimed at augmenting weak T cell responses in elderly immunocompromised individuals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12391215     DOI: 10.4049/jimmunol.169.9.5005

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Finding Balance: T cell Regulatory Receptor Expression during Aging.

Authors:  Mary M Cavanagh; Qian Qi; Cornelia M Weyand; Jörg J Goronzy
Journal:  Aging Dis       Date:  2011-10-28       Impact factor: 6.745

2.  CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype.

Authors:  Yuwen Zhu; Gefeng Zhu; Liqun Luo; Andrew S Flies; Lieping Chen
Journal:  Blood       Date:  2007-01-23       Impact factor: 22.113

3.  Involvement of 4-1BB (CD137)-4-1BBligand interaction in the modulation of CD4 T cell-mediated inflammatory colitis.

Authors:  P Maerten; B S Kwon; C Shen; G De Hertogh; P Cadot; D M A Bullens; L Overbergh; C Mathieu; G Van Assche; K Geboes; P Rutgeerts; J L Ceuppens
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

4.  Immunity, cancer and aging: lessons from mouse models.

Authors:  Cheryl E Myers; Noweeda N Mirza; Joseph Lustgarten
Journal:  Aging Dis       Date:  2011-12-02       Impact factor: 6.745

5.  Targeting CD137 enhances vaccine-elicited anti-respiratory syncytial virus CD8+ T cell responses in aged mice.

Authors:  Sujin Lee; Robert S Mittler; Martin L Moore
Journal:  J Immunol       Date:  2013-11-27       Impact factor: 5.422

Review 6.  Considerations for successful cancer immunotherapy in aged hosts.

Authors:  V Hurez; Á S Padrón; R S Svatek; T J Curiel
Journal:  Clin Exp Immunol       Date:  2016-11-07       Impact factor: 4.330

Review 7.  Optimization of immunotherapy in elderly cancer patients.

Authors:  Kei Tomihara; Tyler J Curiel; Bin Zhang
Journal:  Crit Rev Oncog       Date:  2013

8.  Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease.

Authors:  Alon Monsonego; Victor Zota; Arnon Karni; Jeffery I Krieger; Amit Bar-Or; Gal Bitan; Andrew E Budson; Reisa Sperling; Dennis J Selkoe; Howard L Weiner
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

9.  Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent.

Authors:  Benyue Zhang; Charles H Maris; Juergen Foell; Jason Whitmire; Liguo Niu; Jing Song; Byoung S Kwon; Anthony T Vella; Rafi Ahmed; Joshy Jacob; Robert S Mittler
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

10.  Development of effective vaccines for old mice in a tumor model.

Authors:  David N Posnett; Manuel E Engelhorn; Yun Lin; Taha Merghoub; Fei Duan; Jedd D Wolchok; Alan N Houghton
Journal:  Vaccine       Date:  2008-12-25       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.